Tango Therapeutics, Inc., a biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor that treats cancers with BRCA1 mutations. Tango Therapeutics, Inc. has strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: tangotx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/17/2024 | $19.00 | Buy | Jefferies |
| 4/4/2024 | Overweight | Cantor Fitzgerald | |
| 2/12/2024 | $18.00 | Overweight | Piper Sandler |
| 12/8/2023 | $16.00 | Buy | B. Riley Securities |
| 10/20/2022 | $10.00 | Neutral → Buy | H.C. Wainwright |
| 9/20/2021 | $25.00 | Outperform | SVB Leerink |
| 9/7/2021 | $12.00 | Outperform | Wedbush |
| 9/7/2021 | $20.00 | Outperform | Wedbush |
| 9/7/2021 | $16.00 | Buy | Guggenheim |
| 9/7/2021 | $17.00 | Buy | Goldman Sachs |
Jefferies initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $19.00
Cantor Fitzgerald initiated coverage of Tango Therapeutics with a rating of Overweight
Piper Sandler initiated coverage of Tango Therapeutics with a rating of Overweight and set a new price target of $18.00
B. Riley Securities initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $16.00
H.C. Wainwright upgraded Tango Therapeutics from Neutral to Buy and set a new price target of $10.00
SVB Leerink initiated coverage of Tango Therapeutics with a rating of Outperform and set a new price target of $25.00
Wedbush initiated coverage of Tango Therapeutics with a rating of Outperform and set a new price target of $12.00
Wedbush initiated coverage of Tango Therapeutics with a rating of Outperform and set a new price target of $20.00
Guggenheim initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $16.00
Goldman Sachs initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $17.00
– Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors – – FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA1/2-mutant breast and ovarian cancer; phase 1/2 clinical trial initiation expected 1H 2024 – – Kanishka Pothula, partner at Nextech Ventures, appointed to Board of Directors, replacing Reid Huber, Ph.D., partner at Third Rock Ventures – – Strong cash position of $360 million; cash runway into 2026 expected to fund all clini
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen
– Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-selective PRMT5 inhibition in MTAP-deleted cancers – – FDA clears IND application for TNG260, a first-in-class CoREST complex inhibitor for the treatment of STK11-mutant cancers – – Fast Track designation granted by FDA for TNG260 + anti-PD-1 antibody for the treatment of patients with advanced NSCLC with STK11-loss of function mutations – – Strong cash position of $334 million expected to support advancing precision oncology pipeline into 2026 – BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed
– Fast Track Designation granted to TNG462, next-generation MTA-Cooperative PRMT5 inhibitor – – Adam Crystal, M.D., Ph.D. appointed President of Research and Development – BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2022, and provided business highlights. "2022 was an important year for Tango, as we made critical strides in advancing our programs. We advanced our pipeline of precision oncology programs with the addition of three synthe
BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development. In this executive leadership role, Dr. Crystal will oversee all phases of preclinical research, drug discovery and clinical development. Alan Huang, Ph.D., Chief Scientific Officer, and Ron Weitzman, M.D., Ph.D., Chief Medical Officer, will continue to lead the research and clinical development functions, respectively, as members of Dr. Crystal's team. "Adam is joining at a pivot
NEW YORK and VIENNA, Austria, Dec. 15, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today the promotion of Katia Schlienger, M.D., Ph.D., to Chief Medical Officer and the appointment of Malte Peters, M.D., to its Board of Directors, both effective January 1, 2023. "Katia has had a major impact on HOOKIPA's clinical development strategy and execution in immuno-oncology therapeutics and vaccines since she joined the Company in 2021. She will be leading the progression of our clinical programs to the next level, specifically our own programs in head and n
– Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in France – – TNG260 disclosed as a first-in-class CoREST complex inhibitor for treatment of STK11-mutant cancers – – TNG348 declared as a USP1 inhibitor development candidate for treatment of BRCA1/2 mutant cancers – – Aaron Weitzman, M.D., F.A.C.P., appointed Chief Medical Officer – BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial res
CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced two recent senior management appointments: Marc Rudoltz, M.D., as Chief Medical Officer, and Doug Barry, J.D., as General Counsel. "Marc‘s deep experience in oncology-clinical development, and particular focus on targeted therapy, will be of great benefit as Tango advances into the clinic in the first half of 2022 with TNG908, our MTA-cooperative PRMT5 inhibitor," said Barbara Weber, M.D., president and Chief Executive Officer of Tango Therapeutics. "I'm equally excited
– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway extended into 1Q 2027 with reduction of preclinical spend – BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2025, and provided business highlights. "Accumulating data continue to support TNG462 as the potent
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more info
Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. The election occurred at ITM's Extraordinary General Meeting. Dr. Weber is the President, Chief Executive Officer and Founder of Tango Therapeutics (NASDAQ:TNGX). She has over 25 years of executive and research and development leadership experience in biotech, venture capital and at major pharmaceutical companies, including Novartis (NYSE:NVS) and GlaxoSmithKline (NYSE:GSK). ITM's Supervisory Board and the company overall will benefit from Dr. Weber's deep ex
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois. "The data we are presenting at this year's AACR meeting highlights important preclinical analyses of our PRMT5 programs that underscore the potential of these molecules as both standalone treatments and as key combination partners in MTAP-deleted cancers, including in combin
– TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA. Phase 1/2 enrollment expected to begin 1H 2025 – – Clinical collaboration with Eli Lilly to evaluate TNG456 in combination with CDK4/6 inhibitor Verzenio® (abemaciclib) established – – Data update from ongoing TNG462 monotherapy trial expected in 2025 with focus on pancreatic and lung cancer – – Cash position of $258 million as of December 31, 2024, with cash runway expected to fund operations into 3Q 2026 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics,
BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Feb. 20, 2025-- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Tango Therapeutics management is scheduled to participate in three upcoming investment bank conferences. The B Riley Precision Oncology & Radiopharma Conference will be held in New York, NY in late February. The Leerink Global Healthcare Conference and Barclays 27th Annual Global Healthcare Conference will be held in Miami, FL in March. B Riley Precision Oncology & Radiopharma Conference Panel participation on Friday, February 28 at 9:00-10:00
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on Wednesday, February 5, 2025 at 10:00 AM ET. A live webcast of the fireside chat can be accessed at https://wsw.com/webcast/guggen2/tngx/2036463 and will be available under the "Events & Presentations" tab on the "Investors" page on the Company's website on the day of the event. A
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective December 2, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 187,500 shares of its common stock and 31,250 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan. The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant t
Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Adam Crystal, M.D., Ph.D., President, Research & Development of Tango Therapeutics, is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 1:30 PM ET. A live webcast of the presentation will be available under the "Events & Presentations" tab on the "Investors" page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Tango Therapeutics
– Positive TNG462 clinical activity across multiple tumor types in the phase 1/2 clinical trial, program moving into full development with multiple combination studies – – Clinical collaboration established with Revolution Medicines to evaluate TNG462 in combination with RAS(ON) multi- and G12D-selective inhibitors – – Next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, TNG456, planned to enter the clinic in 1H 2025 – – Strong cash position of $293 million as of September 30, 2024, with cash runway into 3Q 2026 to prioritize resourcing of TNG462 and TNG456 clinical trials – Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discoveri
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4/A - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
S-3 - Tango Therapeutics, Inc. (0001819133) (Filer)
10-Q - Tango Therapeutics, Inc. (0001819133) (Filer)
8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
DEFR14A - Tango Therapeutics, Inc. (0001819133) (Filer)
DEFA14A - Tango Therapeutics, Inc. (0001819133) (Filer)
DEF 14A - Tango Therapeutics, Inc. (0001819133) (Filer)
PRE 14A - Tango Therapeutics, Inc. (0001819133) (Filer)
S-8 - Tango Therapeutics, Inc. (0001819133) (Filer)
10-K - Tango Therapeutics, Inc. (0001819133) (Filer)
8-K - Tango Therapeutics, Inc. (0001819133) (Filer)
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more info
SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)